Overview

An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, non-controlled study to evaluate the efficacy and safety of KHK4827 in subjects with pustular psoriasis (generalized) and psoriatic erythroderma. Pharmacokinetics of KHK4827 will also be assessed.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited
Kyowa Kirin Co., Ltd.
Treatments:
Brodalumab